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ABSTRACT 
 
Introduction 
The aim of this study was to determine the current RPR positive prevalence rate at the 
Johannesburg Hospital and to determine whether there has been a significant decrease in the 
prevalence rate of RPR positive tests. 
 
Patients and Methods 
A retrospective analysis of all RPR results within labour ward registers was performed. A 
sample from 01/08/02 to 31/01/03 was used to determine the current RPR positive prevalence 
rate. The results from the current period were then compared to the results from a similar 
study in 1996. Results of two months, six months apart, of each year between these periods 
were also analyzed in order to determine the trend of RPR positive prevalence rates. 
 
Results 
The RPR prevalence rate was 4.4% compared to 19.5% in 1995/96 (p < 0.0001). Results 
obtained from the intervening years showed a statistically significant decrease. 
 
Conclusion 
RPR positive prevalence rates at Johannesburg Hospital have decreased significantly in 
recent years. 
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INTRODUCTION 
 
Syphilis is a worldwide disease and is the third most common sexually transmitted bacterial 
disease in the United States (after gonorrhoea and chlamydia).1,2 Syphilis infection is 
normally exclusive to humans and is spread by direct sexual contact, congenital infection or 
transfusion with infected blood products.1 Congenital syphilis is now rarely seen in first 
world countries although the prevalence of syphilis in these countries from 1980 – 1995 was 
approximately 7%, having peaked at 13% in 1990.1 In South Africa the average national 
prevalence rate of syphilis in pregnant women has been stated as 6.6%, being higher in some 
regions at 10%.3 Quoted rates include Qolohle et al (6.8%),4 Cronje et al (12-16%),5 Mlisana 
et al (30.7%)6 and Stewart-Smythe  (19-20%).7 
 
Recently, the rapid plasma regain (RPR) positive prevalence rate in the high-risk antenatal 
clinic at Johannesburg hospital seems to have decreased. A large number of the RPR positive 
patients are HIV negative. High viral loads in HIV positive patients are known to be 
associated with false negative syphilis serology.8,9 The aim of this study was to determine the 
current RPR positive prevalence rate in the Johannesburg Hospital maternity unit and to 
determine whether any decrease is real or assumed, by correlating the results obtained from 
pregnant patients admitted to the labour ward with the prevalence of congenital syphilis of 
infants having presented to the neonatal wards as provided by the Department of Paediatrics. 
If congenital syphilis rates remain unchanged, the decrease in maternal syphilis would be an 
assumed one due to false positive results rather than a true decrease. National surveys suggest 
a decline in the prevalence of syphilis.10 The methodology in this study includes verification 
with registers as well as laboratory results to determine whether such a decrease is a real or 
assumed one. 
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The specific objectives of this study were: 
a. To determine the past RPR positive prevalence rate. 
b. To determine the current RPR positive prevalence rate. 
c. To determine an approximate RPR positive prevalence rate for each year from past to 
current periods. 
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CHAPTER 1 
SYPHILIS IN CONTEXT 
 
1.1 What is syphilis? 
1.1.1 Definition  
Venereal syphilis, which the broad term syphilis has come to denote, is a sexually 
transmitted bacterial infection caused by the spirochete Treponema pallidum.11 
1.1.2 Pathophysiology 
Untreated, syphilis progresses through three symptomatic stages. Primary and secondary 
syphilis are highly infectious stages characterized by rapid division of organisms. Since 
primary syphilis presents with a painless ulcer or chancre, infection may go unnoticed. 
The mucocutaneous rash of secondary syphilis is transient and may also go unrecognized 
resulting in lack of treatment and disease progression. Latent syphilis refers to 
asymptomatic infection which may be early, if within a year of onset of infection, or late, 
if greater than a year of onset of infection. Early latent syphilis may present with recurrent 
mucocutaneous rash as the organisms are still in a state of rapid division. During late 
latent syphilis and tertiary syphilis organisms are thought to be dividing more slowly, 
necessitating longer duration of therapy. The gummatous lesions of tertiary syphilis are of 
concern as these result in cardiac, ophthalmic, and auditory abnormalities as well as 
neurosyphilis which may result in focal ischemia, stroke or psychiatric manifestations.1, 2, 
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1.1.3 Incidence 
The incidence of the disease has steadily decreased with the advent of penicillin in the 
early 1940s. The prevalence of syphilis in first world countries from 1980 – 1995 was 
approximately 7%, having peaked at 13 % in 1990.1 With time and public health control 
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measures, rates of primary and secondary syphilis reached a nadir in 2000 in the United 
States. Since then, despite a continued decline in women and infants, overall rates have 
begun to increase. However, these are so low that they are now expressed per hundred 
thousand rather than as a percentage, being between 2-4/100 000 new infections per year 
from 1997-2004.12, 13 In South Africa, the average national prevalence rate of syphilis in 
pregnant women had in 1997 been stated as 6.6%, being higher in some regions at 10%.3 
Quoted rates from 1990 – 1997 include Qolohle et al at 6.8%,4 Cronje et al at 12 – 16%,5 
Mlisana et al at 30.7%,6 and Stewart-Smythe at 19-20%.7 The ‘National HIV and Syphilis 
Antenatal Sero-prevalence Survey in South Africa’ showed a graphical decline in syphilis 
from 10-12% in 1997-1998 to 2-4% in 2002-2004.10 The quoted South African rates are 
all from studies of the pregnant population. However, rates from the United States are 
population based and reflect men, women and infants across all states. 
 
1.2 Why is syphilis of importance in obstetrics and gynaecology? 
1.2.1 Congenital syphilis 
Congenital syphilis refers to the transplacental passage of spirochetes.11 The Centers for 
Disease Control, for the purposes of notification, includes in its definition of congenital 
syphilis, stillbirths associated with syphilis and the infants of mothers who were 
inadequately treated or untreated for syphilis, irrespective of the findings in the infant.14, 
15, 16 This definition is of paramount importance as transmission to the fetus approaches 
100%. More than 40% of untreated pregnancies will result in perinatal demise. Surviving 
infants may present with early manifestations (< age 2 years) or late manifestations (> age 
2 years). Since the fetus does not mount an inflammatory response prior to 12 weeks 
gestation, organogenesis is not affected (although treponemes rarely cross the placenta in 
the first trimester). All organs may however be involved by the infection.11 Any stage of 
syphilis occurring during pregnancy may result in an infected fetus and congenital 
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syphilis usually occurs when treponemes cross the placenta after the 16th-18th week of 
gestation. Infection may rarely occur from contact with an infectious lesion during 
delivery.17 Spirochetaemia results in vasculitis and resultant necrosis and fibrosis in target 
organs.18 Fetal manifestations include spontaneous abortion, intrauterine growth 
restriction, non-immune hydrops fetalis, stillbirth, preterm delivery and perinatal death. 
Congenital syphilis can present along a broad clinical spectrum with a range of laboratory 
and radiological findings involving many organs. {See table 1, adapted from ‘Sex. 
Transm. Inf. 2000; 73-79’}. If adequately detected and treated, these consequences can be 
avoided. 
 
 
Table 1: Presentations of congenital syphilis 
(Adapted from ‘Sex. Transm. Inf. 2000; 73-79’) 
Clinical findings            Percentage 
 
Early 
 Abnormal bone X-ray     61 
 Hepatomegaly      51 
 Splenomegaly      49 
 Petechiae      41 
 Skin lesions      35 
Anaemia      34 
 Lymphadenopathy     32 
 Jaundice      30 
 Pseudoparalysis      28 
 Snuffles      23 
Late 
Frontal bossing      30 – 87  
Palatal deformation     76 
Dental dystrophies*     55 
Interstitial Keratitis*     20 – 50 
Abnormal bone X-ray     30 – 46 
Nasal deformity (saddle deformity)*   10 – 30  
Eight nerve deafness     3 – 4 
Neurosyphilis      1 – 5 
Joint disorder      1 – 3 
 
* Hutchinson Triad 
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1.2.2 Co-morbid disease and a review of risk factors 
Co morbid disease includes HIV infection as well as other sexually transmitted infections 
(STIs). Cross infection of STIs has been widely recognized and has led to the advent of 
syndromic management. Mathews et al however found that despite the introduction of 
syndromic protocols, a fair proportion of STIs and genital tract infections were not being 
detected and treated due to the high prevalence of multiple syndromes and mixed infections.19 
The complications of inadequate treatment and persistent infection then present to the 
gynaecologist as advanced disease and sometimes generalized sepsis increasing morbidity, 
hospital stays and mortality. 
 
Venereal syphilis is a sexually transmitted disease sharing the same risk factors as other 
sexually transmitted genital tract infections. This includes sexually active females, aged 16-
25 years, who do not use contraception and live in areas with a high prevalence of STIs.20 
Age at first intercourse, unmarried status, and the number of sexual partners have all been 
proven to be risk factors for genital ulcer disease occurring secondary to other STIs. Also, 
genital ulcerations and inflammation secondary to STIs have been implicated as cofactors for 
acquisition and transmission of HIV.21, 22 The increased infection rate in teenagers is thought 
to be secondary to the lower level of antibodies and the wider area of cervical columnar 
epithelium allowing colonization with various organisms.20  
 
An epidemic in a region is believed to be promoted by multiple factors including the 
aforementioned high prevalence of STIs,23 poor access to effective STI treatment, sexual 
networking patterns prevalent in the area, and the disruptive effects of the migrant labor 
system.24, 25, 26 Wilkinson et al attest to South Africa’s massive, often unrecognized burden of 
STIs, having found that although rates were highest in women who engaged in high risk 
behavior such as sex work, rates were also high amongst women in the general community 
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considered to be of lower risk. In a study done in rural Kwa-Zulu Natal, they found that 77% 
of sex workers had at least one STI and 33% had multiple infections. Pregnant women 
showed corresponding rates of 52% and 18%, and women attending family planning clinics 
had rates of 27% and 10% respectively. Prevalence of HIV infection in each of these groups 
was also found to be high at 50%, 16% and 24% respectively. Underlying factors identified 
by this group included poor quality services, low rates of partner treatment, poor 
understanding of and response to symptoms, sex work, and high levels of population mobility 
and migration.27 STDs and HIV were also found to be frequent along major arterial routes, 
the communities along these routes having the greatest prevalence of these diseases.28 
 
1.3 Diagnostic modalities. 
Spirochete visualization by darkfield microscopy and the use of direct fluorescent antibody 
tests comprise the definitive methods of diagnosing syphilis from a genital ulcer (early 
syphilis). These are most specific when the chancre or condyloma is present. A microscope 
with a dark-field condenser or a phase contrast microscope is used to observe motile 
organisms with a corkscrew appearance. At least 104 organisms need to be seen so a negative 
test does not rule out syphilis unless the exam has been repeated on three consecutive days.29 
 
Serological tests for diagnosis may be nonspecific nontreponemal tests, or specific 
treponemal tests. These are most often only positive from about the fourth week of acquired 
syphilis, which has an incubation period ranging from 10 to 90 days. 
 
1.3.1 Nonspecific or lipoidal antigen tests: 
These include:  
 Venereal Disease Research Laboratory (VDRL) 
 Rapid Plasma Reagin (RPR) 
 15 
 Treponemal enzyme assay (ELISA) 
 Wasserman Reaction (WR) 
 
These tests are based on antibodies against nontreponemal antigens, for example antigen 
extracts from beef heart (cardiolipin)30 and allergy related immunoglobulin E (IgE), which 
are released by human tissue infected with Treponema pallidum. The tests may be positive in 
other conditions associated with this release. Because they are characterized by the 
inflammatory response of the primary reaction, these tests often become non-reactive 
following successful treatment. However, low or negative titres may occur with longstanding 
disease. The RPR test is used for syphilis detection only. Sensitivity in the primary stage is 
only 30% after one week of infection in the primary stage, 90% after three weeks as well as 
in the tertiary stage, and approaches 100% in the second stage of the disease.31 The VDRL 
test can be used not only for syphilis detection, but also for quantitative analysis.32 Some 
patients demonstrate a serofast reaction where nontreponemal antibodies persist after 
treatment for a long period of time and sometimes even for the lifespan of the patient. False 
positives may occur with systemic lupus erythematosus, malaria, infectious mononucleosis, 
infectious hepatitis, post-vaccination state, leprosy, brucellosis, atypical pneumonia, miliary 
tuberculosis, typhus, pregnancy, and related treponemal infections such as yaws, pinta and 
bejel.30 The specificity of these tests is 75-85% in patients with such pre-existing diseases, but 
approaches 100% in patients without them.33 Causes of false negative results are few. 
Patients with extremely high titres may have false negative results which become positive 
only after sera dilution. In the advanced stages of HIV infection, patients do not mount an 
appropriate immune response and hence may have false negative tests. 
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1.3.2 Specific treponemal antigen tests: 
These include: 
 Treponema Pallidum Haemagglutination Assay (TPHA) 
 Fluorescent Treponemal Antibody Absorbed (FTA-ABS) test 
 Micro-Haemagglutination Assay for Treponema Pallidum (MHA-TP) 
 Treponemal Enzyme-linked Immunosorbent Assay (ELISA) 
 Treponema Pallidum Immobilization Test (TPI) 
 
These tests are only indicated for confirmation of positive syphilis serology.34 With these 
tests, specific serum antibodies against treponemal antigens are detected so although fairly 
specific for syphilis, other treponemal diseases such as yaws, bejel and pinta cannot be 
excluded. Reactive treponemal tests usually remain reactive for the remainder of the patients’ 
life irrespective of treatment or disease activity. However, up to 25% of patients treated 
during the primary stage may revert to being serologically non-reactive after two to three 
years.35 
 
Both specific and nonspecific diagnostic tests for syphilis are generally reliable in HIV 
positive patients, although some may have atypical test results due to deregulation of immune 
responses. HIV positive patients show a varied immune response. In early infection, there is 
an abnormal antibody response with loss of clones of antibodies. This may interfere with 
serology of both specific and nonspecific tests. In advanced stages of the disease there is no 
longer adequate functioning of the immune system to mount an immune response.36, 37 If the 
clinical syndrome is highly suggestive one should the resort to biopsy and direct microscopy. 
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1.4 Screening 
Screening in pregnancy implies measures taken to detect disorders of which the patient has 
no signs and symptoms, but are likely to have an adverse effect on the well being of mother 
or fetus, and for which effective intervention is available and necessary.17, 38 
 
1.4.1 Recommendations and rationale 
Recommendations and the rationale thereof have been instituted by various antenatal 
screening review committees worldwide and are guided by Centers for Disease Control 
(CDC), Royal College of Obstetricians and Gynaecologists (RCOG), National Institute of 
Clinical Excellence (NICE), American College of Obstetricians and Gynaecologists (ACOG) 
and U.S Preventative Services Task Force (USPSTF) guidelines as well as guidelines from 
various state departments, pathology groups, paediatric and midwifery committees.33, 38, 39, 40, 
41 
 
The Three Centre Consensus Guidelines on Antenatal Care issued specific guidelines for the 
antenatal screening of syphilis with the following levels of evidence.39 
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Table 2: Specific guidelines for the antenatal screening of syphilis 
(Adapted from Three Centres Consensus Guidelines on Antenatal Care Project) 
Guidelines Level of Evidence 
Early in pregnancy all women should receive appropriate written 
information about antenatal syphilis testing and be given the 
opportunity to discuss it with their midwife or doctor. 
IV 
Antenatal serological screening for syphilis should be offered to 
all pregnant women 
III-2 
IV 
Screening for syphilis should be undertaken at the first antenatal 
visit, ideally prior to 16 weeks gestation 
IV 
III: “Evidence obtained from well-designed non-experimental descriptive studies, such as 
comparative studies, correlation studies and case studies” 
IV: “Evidence obtained from expert committee reports or opinions and/or clinical experience 
of respected authorities.” 
 
 
Presented below is a summary of recommendations for screening for syphilis infection 
(antenatal and other) as released by the USPSTF (United States Preventative Services Task 
Force) in July 2004.41 These recommendations are deemed necessary for control of antenatal 
and hence congenital syphilis, and also address a more holistic approach necessary to control 
the disease within an evidence based framework. 
 
• ‘The USPSTF strongly recommends that clinicians screen persons at increased risk 
for syphilis infection.’ Grade A recommendation 
Rationale: “Although the potential harms of screening, including false positives, 
patient anxiety and antibiotic related risks are recognized, the USPSTF feels that 
benefits of screening high risk persons substantially outweigh the risks as screening 
tests accurately detect syphilis infection and antibiotics provide cure. However, no 
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direct evidence was found to prove that screening for syphilis leads to improved 
health outcomes in such high risk persons.” 
 
• ‘The USPSTF strongly recommends that clinicians screen all pregnant women for 
syphilis infection.’ Grade A recommendation 
Rationale: “Benefits of such screening substantially outweigh potential harms since 
the proportion of infants with clinical manifestations of syphilis infection and with 
positive serologies is reduced as a result.” 
 
• ‘The USPSTF recommends against routine screening of asymptomatic persons who 
are not at increased risk for syphilis infection.’ Grade D recommendation 
Rationale: “Harms of screening in the low risk population outweigh risks as the 
incidence of syphilis in the general population is low.” 
 
1.4.2 Standards for screening 
In South Africa, although antenatal screening for syphilis is advocated, no guidelines exist as 
to the standards for such screening. Patients are at most told that they are being tested for 
syphilis and at follow up visits they may be informed of their results. Often patients only get 
to know their results if they require treatment. The figure below illustrates an example of 
minimum standards that apply in first world countries for the antenatal screening of 
syphilis.38 
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Figure 1: Minimum standards for the antenatal screening of syphilis 
(Adapted from Making decisions: Standards Protocols and the Performance Management Framework 
to support the provision of Antenatal Screening in Wales: A Consultation Document; 2004) 
 
 
Minimum standards for antenatal screening for syphilis 
 
5.4.1 The woman’s informed verbal consent is required and a record of her consent must be made in the 
maternity notes. 
 
5.4.2 Whenever possible screening should be offered and undertaken before 13 weeks of pregnancy to enable 
treatment to start promptly and reduce the risk of fetal damage. 
 
5.4.3 A record of the serum test being taken must be made in the maternity notes. 
 
5.4.4 The laboratory request form must require the identification of the sample as ‘antenatal screening’. If a 
single request form is used for multiple screening tests, the form must contain a clear indication of the 
screening tests which the woman has given consent. 
 
5.4.5 All relevant clinical information must be included on the request form. 
 
5.4.6 The test should normally be undertaken by a laboratory which is accredited or approved by CPA UK 
Ltd. 
 
5.4.7 It is recommended that the screening test assay has a high sensitivity ideally at least  99% and a high 
specificity (99.95%). 
 
5.4.8 The test result must be provided by the laboratory to the Trust Powys LHB within 7 working days. 
 
5.4.9 All women must be informed by the Trust Powys LHB of the result within 15 working days. 
 
5.4.10   If the screening test is negative the woman should be informed that she has a low chance of having the 
condition at present. 
 
5.4.11   Confirmed syphilis positive test results indicating current infection should be telephoned to the 
consultant, screening midwife or named deputy so urgent arrangements can be made for the woman to 
return to the clinic for the result. The result should not be electronically be transferred from the 
laboratory to the maternity or other services unless appropriate security arrangements are in place to 
ensure the result can only be accessed by locally agreed named individuals. 
 
5.4.12   As syphilis is a rare condition in the UK, all women testing positive should be referred to a specialist in 
Genitourinary Medicine (GUM) for assessment and counselling. 
 
5.4.13   The woman’s suspected or confirmed syphilis positive result should not be:  
• recorded on the maternity information system without the woman’s informed consent  
• written in an appropriate way in the hospital maternity notes  
• on blood request forms or other request forms where hospital staff unconnected to the woman’s 
care will have unnecessary access to this information. 
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It becomes clear from the above minimum criteria that we in South Africa are sadly deficient 
in our approach to antenatal screening for syphilis. At a bare minimum, one should follow the 
CDC recommendation that ‘no infant should leave the hospital if maternal serologic status 
has not been determined at least once during pregnancy and preferably again at delivery’ with 
reference to syphilis serology.2 
 
1.4.3 On-site screening 
The rationale for on-site screening for syphilis is based on the premise that in a third world 
country such as our own, pregnant women often initiate antenatal care late in pregnancy. 
Since between 2 weeks and a month may elapse prior to the follow-up visit, appropriate 
management of a positive test is delayed. This may result in women giving birth before being 
treated for syphilis and does not effectively prevent congenital syphilis. On-site screening 
would enable immediate diagnosis and initiation of treatment of these patients.42 A South 
African study investigated the RPR card test as a screening test to diagnose the presence of 
syphilis as well as titres. The on-site RPR test had a sensitivity of 92.8%, a negative 
predictive value of 99.5%, a specificity of 96.3% and a positive predictive value of 64.7% 
showing that maternal syphilis could be diagnosed in the majority of cases screened on-site at 
their initial visit.42 Although active syphilis is denoted by an RPR titre of 1:8 or greater, the 
risk of fetal infection becomes more likely if the RPR titre is greater than 1:16.43 For RPR 
titres greater than or equal to 1:8 the on-site RPR card had a sensitivity of 90.5% although for 
titres greater than or equal to 1:16 the sensitivity approached 100% implying that all patients 
at risk for congenital syphilis could be identified and treatment initiated on-site.3 This does 
compare with the sensitivity and specificity of conventional RPR testing. This has far 
reaching consequences in a South African setting where patients present late and minimum 
standards for screening are poorly defined. The CDC has recognized this and hence 
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recommends that where prenatal care is not optimal, such card screening and treatment be 
performed.2  
 
1.4.4 Re-screening 
The CDC recommends that in areas of high prevalence, screening should be done in early 
pregnancy, in the third trimester and at delivery.2 The rationale for this is to lower the 
incidence of congenital syphilis by decreasing the prevalence of maternal syphilis. In the 
South African context, Opai-Tetteh et al made a case for re-screening in areas of high 
prevalence, having identified a higher seroconversion rate at King Edward VIII Hospital in 
KwaZulu Natal as compared to Tygerberg Hospital in Cape Town.44 
 
1.4.5 Screening Considerations 
The stage of infection may well complicate screening. Women tested too early (less than 
three weeks from onset of infection) may show false negatives.31, 45 This would be more 
likely in areas of high prevalence than in the general population. The syphilitic ulcer is 
generally painless and transient and may be missed by the patient herself, as well as the 
health care worker who does not do a vulval and vaginal examination. 
 
Also, any woman who has a stillbirth after 20 weeks gestation should be screened for 
syphilis.2 
 
 23 
1.5 Treatment 
 
1.5.1 Patient 
When determining appropriate therapy, many factors need consideration. These include the 
stage of maternal infection, the physiological changes of pregnancy which alter drug 
pharmacokinetics, the effect of the drugs on the fetus, penicillin allergy and HIV co-
infection.45 
 
For this reason, patients with titres of above 1:8 should receive standard treatment as outlined 
below. Patients with titres of 1:8 and below should ideally be re-screened with one of the 
specific treponemal tests and only be treated in the event of this being positive. This would 
prevent unnecessary treatment of the false-positive patient. South African National Maternity 
Guidelines are however to treat all patients who are RPR positive, irrespective of titre. This is 
due to problems with follow-up, cost and the possibility that a specific test is very likely to 
come back positive as a result of old infections. 
Penicillin is the treatment of choice for the treatment of syphilis and is also safe in pregnancy 
and during breastfeeding.46 The CDC recommends that treatment during pregnancy should 
comprise a stage-appropriate penicillin regimen. Women with primary, secondary or early 
latent syphilis should receive a second dose of benzathine penicillin one week following the 
initial dose.2,46 The policy in South Africa is to treat maternal syphilis with Benzathine 
benzylpenicillin, IMI, 2,4 MU weekly for three doses.47 In the South Africa context patients 
often present late and the health care worker is unable to ascertain the stage of syphilis 
making this recommendation appropriate. This is supported by clinical microbiology 
guidelines for treatment of syphilis in pregnancy of unknown duration.48 
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Some patients may display an acute febrile reaction accompanied by flu-like symptoms 
within the first 24 hours of any therapy for syphilis. This is known as the Jarisch-Herxheimer 
reaction and should not deter therapy. Patients should however be informed of the risk 
thereof and that such reaction may result in fetal distress or preterm labor.2, 46 Therefore, 
although no guidelines exist as to prevention of such risk, it would be better to admit patients 
with such flu-like symptoms for observation for 24 hours. 
 
1.5.2 Fetus 
Treatment of the mother prior to the 16th week of gestation completely eradicates the 
infection and its sequelae. It is thought that treponemes cannot cross the Langhans cell layer 
of the placenta which only begins to atrophy at 16 weeks of gestation. Treatment from 16 
weeks of gestation does cure infection but may not prevent stigmata of congenital syphilis. 
Kassowitz’s law is that pregnancy in a woman with early syphilis generally ends in fetal 
demise, subsequent pregnancies result in fetuses with congenital syphilis and still subsequent 
pregnancies may not be affected. This is due to bacteraemia which may persist as long as 8 
years untreated.48 
 
Fetal infection may still occur in up to 14% of appropriately treated cases.45 Ultrasound signs 
of fetal syphilis include signs such as hepatomegaly or hydrops fetalis and may indicate 
fetuses at increased risk of treatment failure even before commencing therapy. Such fetuses 
will need close follow-up and a second course of therapy may well be warranted. If the fetus 
is severely infected prior to initiating therapy, the Jarisch-Herxheimer reaction may result in 
preterm labor or fetal death.48 
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1.5.3 Partner 
To prevent the spread of sexually transmitted disease, treatment of the partner has always 
been advocated. With syphilis, sexual transmission only occurs when there are 
mucocutaneous lesions and these are rare after one year of infection. Sexual partners however 
still warrant evaluation. South African guidelines mandate examination and treatment of the 
sexual partner.47 The CDC recommends treatment of partners presumptively in persons 
exposed to the patient within 90 days of the diagnosis of primary, secondary or early latent 
syphilis, as a serological test may be falsely negative within this time. For those exposed for a 
period of longer than 90 days, treatment should be given if loss to follow up is a problem or if 
test results are not available immediately. Otherwise, the partner should be tested and treated 
depending on their result although a titer of greater than 1:16 may not necessarily mean early 
syphilis and response therefore should ideally be monitored by subsequent follow up and 
serological titers.2 The recommended regimen for treatment is Benzathine penicillin 2.4 
million units IMI as a single dose. 
 
1.5.4 HIV co-infection 
Aberrant serological responses may occur in the patient infected with HIV. These range from 
higher serological titers to false negative results and a longer time span to seropositive 
results. Since these occur more as exceptions to the rule and are not regular occurrences, 
specialists feel normal interpretation of serological tests should apply.2 If clinical suspicion is 
high and the test result does not concur, repeat testing or biopsy of lesions present can be 
done and sent for darkfield microscopy. Although the CDC recommends treatment of these 
patients with a single dose of benzathine penicillin, they also acknowledge that in these 
patients some specialists recommend repeat doses weekly for a total of three doses.2 This is 
the recommendation adhered to in pregnancy and is no different from that in the patient 
without HIV co-infection. 
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1.5.5 Penicillin-allergic patient 
Doxycycline or tetracycline are alternative therapies to penicillin in the non-pregnant patient.2 
These drugs are not safe for use in pregnancy and hence not recommended for the treatment 
of maternal syphilis. The policy for the treatment of maternal syphilis from the South African 
Department of Health is to treat the penicillin sensitive patient with erythromycin, oral, 
500mg, 6 hourly for 28 days and to give penicillin to the baby after delivery.47 Although 
erythromycin, azithromycin or ceftriaxone can be used in pregnancy; the treatment of syphilis 
in pregnant patient who is allergic to penicillin poses a problem since no alternative to 
penicillin has proved effective in the treatment of syphilis during pregnancy. Erythromycin 
does not reliably cure an infected fetus as it does not reliably cross the placenta, and no 
adequate data exist for the use of azithromycin and ceftriaxone in this regard.2,48  
 
It is essential therefore, for the penicillin allergic mother, to consider desensitization. Most 
patients reporting penicillin allergy may not display hypersensitivity because the 
hypersensitivity has faded or they were never allergic to penicillin.46 Although between 3 and 
10% of studied populations have experienced urticaria, angioedema or anaphylaxis following 
penicillin therapy, only 10% of patients who report severe allergic reactions actually remain 
allergic. In these however, re-administration could cause acute severe and fatal anaphylaxis.2 
Skin testing (90% -97% sensitivity) with major and minor determinants is therefore necessary 
in patients with a history of penicillin sensitivity. Patients who no longer express IgE 
antibodies will not elicit a reaction and can be safely treated with penicillin. For patients 
proven to be sensitive or for whom the full battery of skin tests is not available, 
desensitization in a hospital setting must be done. This can be either oral or IVI and takes 
approximately 4 hours to complete (see figure 2). Maintenance on penicillin is then necessary 
until the full course of therapy is completed.2 
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Figure 2: Suggested penicillin desensitization protocol 
(Adapted from Sexually Transmitted Diseases Treatment Guidelines; 2002) 
 
 
 
1.5.6 Congenital syphilis 
Congenital syphilis may result in stillbirth, hydrops fetalis or prematurity.48 Much of 
detection and prevention of congenital syphilis is dependent on antenatal screening. Routine 
screening of newborn sera is inadvisable since these can be negative depending on the pre-
delivery maternal titer or if the mother was infected late in pregnancy. Also passage of 
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maternal IgG antibodies across the placenta further complicates diagnosis in the newborn. 
Currently no commercially available IgM antibody test can be recommended.2 If the maternal 
RPR result is unknown at delivery, it should still be tested in preference to that of the 
newborn. 
 
Clinical microbiological and CDC guidelines concur on the assessment and treatment of 
infants who fit the definition of congenital syphilis and are displayed below.2,48 
 
Figure 3: Guideline for the management of the infant born to a mother with reactive 
treponemal serology in pregnancy 
(Adapted from Clinical Microbiology Guidelines; January 2005) 
 
 
Management of the infant 
 
All infants of mothers who were treated for syphilis before or during pregnancy, should be fully 
examined clinically at birth and at six weeks, 3, 6 and 12 months of age. Serological testing with 
quantitative RPR should be performed at birth and at 3, 6 and 12 months.  
 
• If the mother was treated with an appropriate course of penicillin and has shown 
reduction in three, the infant should be monitored serologically as above. Full 
evaluation and treatment for congenital syphilis will be necessary in such cases only if 
there is a rise or persistence of titre and/or clinical or radiological evidence of disease. 
 
An infant should be evaluated for congenital syphilis if he/she was born to a mother with a positive 
specific treponemal test and one or more of the following conditions are operative : 
 
1.  The mother received no treatment. 
2.  The treatment given to the mother is not known. 
3.  The treatment given to the mother is inadequate. 
4.  The probability of follow-up is uncertain. 
5.  The mother was treated with an antibiotic other than penicillin (erythromycin usually) 
6.  Treatment was with penicillin but the expected decrease in nontreponemal antibody titre 
after treatment did not occur. 
7. Appropriate treatment was given but there was insufficient serological follow-up to assess 
the response to the treatment and the current infection status. 
8.      Treatment was less than one month before delivery.  
 
• In each of these cases above, the infant should be admitted for evaluation for congenital 
syphilis. Treatment should commence with minimal delay in each of the above scenarios 
regardless of the findings (see Table and Algorithm). 
 
• In addition, any infant with physical or laboratory findings consistent with a diagnosis of 
congenital syphilis should be treated without delay.  
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Recommended regimens for treatment of infants who fit the criteria for congenital syphilis 
include:2 
• Aqueous crystalline penicillin G; 100000–150000 units/kg/day *10 days in 
divided doses 
• Procaine penicillin G; 50000 units/kg/dose IMI once daily *10 days 
• Benzathine penicillin G; 50000 units/kg/dose IMI stat 
 
1.6 Psychosocial issues 
 
Epidemiological studies have shown that a major contributor to the increased risk of 
congenital syphilis was a lack of antenatal care. Women most likely to infect their fetuses 
with syphilis often have complex dilemmas impeding their access to screening and treatment. 
Psychosocial issues that make medical treatment goals difficult to achieve and that have been 
associated with syphilis include low education levels, teenage pregnancy, HIV infection, 
cocaine use and underutilization of health infrastructure.45 Training of health care workers 
addressing such communities centers on reducing sexual prejudices and adopting an attitude 
toward reproductive health which allows for the sexual lifestyle of the user within their own 
context. Health service reform stresses a rights-centered approach providing free and 
informed consent to these patients and respecting their rights especially with regard to 
prenatal, antenatal and postnatal care, as well as STD treatment and family planning. For this 
to be successful, a community orientated approach, coordinated with a base institution is 
necessary. Accessibility needs to be facilitated.49 
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1.7 Follow-up 
 
Although treatment of maternal syphilis is usually highly effective, treatment in the third 
trimester is more likely to fail. Treatment failure can occur but is less likely in earlier 
trimesters. Monthly serological follow-up for the remainder of the pregnancy is therefore 
recommended. High titer syphilis should show up to a four fold drop and low titer syphilis 
should remain stable. The persistent of ultrasound markers of fetal syphilis following therapy 
may also indicate treatment failure.48 In either of these scenarios re-treatment is necessary. In 
the United Kingdom such patients should also be referred to genitourinary medicine (GUM) 
clinics for counseling, postpartum follow up and screening for other STDs. All infants who 
are treated following positive maternal serology should ideally be followed up at 6 weeks, 
and have repeat serology at 3, 6 and 12 months of age.48 HIV infected patients should be 
followed up at 3, 6, 9, 12 and 24 months following therapy to assess for treatment failure. 
Those who meet criteria for treatment failure should be referred appropriately for re-
treatment and investigation for neurosyphilis.2 Infrastructure for such follow-up is the ideal to 
adequately manage these patients and prevent further spread of the disease but is largely 
unavailable in the third world context. 
 
1.8 The concept of prevention and elimination 
 
Syphilis infection is normally exclusive to humans and is spread by direct sexual contact, 
congenital infection or transfusion with blood products.1 Any disease that is exclusive to 
humans can potentially be eradicated not unlike the worldwide effort with poliomyelitis. This 
concept has been addressed by the syphilis elimination effort in the United States. 
 
 31 
1.8.1 Worldwide 
In 1999, the CDC initiated ‘The National Plan to Eliminate Syphilis’ from the United States. 
The rationale for this was the declining rates of syphilis in the United States in the preceding 
decade. The plan focused on populations having the highest prevalence of syphilis and has to 
date shown a decline in these populations. However an increase was noticed in a group not 
focused on; that being the ‘men who have sex with men’ group.13 
 
Syphilis elimination has been defined by the CDC as the absence of sustained transmission of 
the disease.50 The burden of disease, including increased HIV transmission and congenital 
syphilis was appropriately highlighted. Recognition that a conscious effort to eliminate 
syphilis would result in decreasing such comorbidities is central to such an effort. The 
presence of genitourinary medicine clinics is part of the essential infrastructure for the 
success of such an effort. It is not surprising then, that the three goals guiding this plan 
include: 
• Investing in and enhancing public health services and interventions 
• Prioritising and targeting populations at risk 
• Improving accountability of prevention efforts 
 
The above goals highlight improved surveillance, recognition, treatment and prevention of 
the disease. The importance of adequate interaction with laboratory and testing sevices as 
well as the private health care sector is recognized. Integral to the process is staff training, 
ongoing research and data or research driven planning and integration.50 The CDC has been 
implementing the above plan with a prospective five year timetable of activities dictating 
progress. Such a timetable is integral to the success of such an initiative. 
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1.8.2 The South African context 
The burden of sexually transmitted disease including syphilis in a third world country is even 
more apparent, paving the way for comorbidities and HIV infection. Stabilisation of 
prevalence rates of syphilis is essential for a syphilis elimination effort, hence the need for 
ongoing research into syphilis prevalence trends. The lack of specified genitourinary 
medicine clinics serves as a drawback in infrastructure. Primary health care facilities, 
excellent research units and support networks such as Thetha Junction can however assist in 
the initiation of this much needed infrastructure within a cost-effective strategic plan. 
 
Integration of services encompasses creation of health facilities in order to optimize 
prevention and care strategies, hence saving time and providing quality health care. In Latin 
America ‘Maternal-child health and sexually transmitted diseases and HIV/AIDS integration’ 
is one of the integrations related to reproductive health. It promotes testing for HIV and 
syphilis in order to decrease mother to child transmission of these diseases. Similarly, ‘New 
populations and available family planning or STD and HIV/AIDS services integration’ was 
aimed at addressing other populations at risk of sexually transmitted diseases in the Latin 
American context.49 
 
In South Africa, the National STI initiative has addressed similar issues. STIs were 
recognized as a major health priority in South Africa because of their associated morbidity 
and mortality. Four sites were selected as pilot sites for intervention, focusing on STI 
management and prevention within the public health sector through monitoring and 
evaluation, training and support. Guidelines were then issued based on the successes and 
failures at the four selected sites.51 
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Figure 4 summarizes the approach that was used by the Reproductive Health and Research 
Unit (RHRU) in the STI initiative. 
 
Figure 4: STI Initiative to Improve STI care at a District Level: The Quality Assurance 
Cycle. 
(Adapted from Guidelines for Improving Quality of STI Management in a Health District, 
RHRU) 
 
 
From this project, it was found to be essential to identify a team of people committed to 
improving the quality of STI care. The teams involved in this circumstance were motivated 
enough to undertake a number of initiatives, some of which became implemented at a 
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national level.  The initiatives included compiling a workbook to support clinical training, 
encouraging STI contact tracing in local languages, monitoring performance at a clinic as 
well as a sub-district level and contacting the relevant centers to alleviate drug shortages. Key 
officials were mobilized in order to achieve goals. This entailed co-operation between 
officials of local and provincial authorities.51 
Another initiative by the RHRU which shows progress and initiative in the South African 
context is the ‘National Survey of HIV and Sexual Behavior among Young South Africans’. 
This survey comprised of comprehensive analysis of sexual and behavioral information and 
HIV testing in the 15 – 24 year old age group.52 The survey shows that the youth of South 
Africa are indeed at risk of HIV infection with one in ten of them currently being infected. 
More than two thirds changed their sexual behavior once aware of their risk and many 
increased their use of condoms. Many however underestimated their personal risk of 
infection.52 Much literature regards age 16 – 25 as being the age group at highest risk of 
STI’s, including syphilis. Such a survey is therefore integral in approaching the burden of 
STI’s in the South African context and can be used to positive effect in the initiation of a 
syphilis elimination effort in this country.  
‘The National STI/HIV Baseline Assessment 2002/2003’ consisted of telephonic surveys of 
prmary health care facilities throughout South Africa, looking at facility description, staff 
allocation, numbers of STI patients, knowledge of drugs used in syndromic management, 
drug availability for syndromic management, antenatal syphilis screening, staff training in the 
management of STI’s, HIV management and condom distribution.53 The initiative found that 
only half of professional nurses working within primary health care facilities were trained in 
syndromic management of STI’s. As a result treatment quality was compromised by 
insufficiently trained staff and inappropriate use of antibiotics available. Clinical assessment, 
counseling and record keeping were also compromised. As a result less than 50% of facilities 
provided appropriate treatment for vaginal discharge, urethral discharge and genital ulcers.53 
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Such an initiative is key to providing the infrastructure and training necessary for syphilis 
elimination. 
 
The RHRU has therefore contributed with excellent surveys to the improvement of STI care 
within South Africa and such care, if optimally initiated can be used in designing an approach 
to the elimination of Syphilis within a South African context. 
 
1.8.3 Is syphilis declining in South Africa? 
In October 2004, the National Department of Health conducted the fifteenth National HIV 
and Syphilis Antenatal Sero-prevalence Survey. The primary objective of this survey was to 
provide information on the prevalence of HIV and syphilis among pregnant females attending 
antenatal care in the public sector. The study design was a cross-sectional, anonymous 
unlinked survey among women attending antenatal care at selected sites in the nine provinces 
across South Africa. All pregnant women attending antenatal care for the first time in the 
index pregnancy were eligible for inclusion. The survey was conducted in October 2004. 
Blood, labeled with barcodes that were used on data collection sheets, was collected from the 
women. HIV ELISA tests were done and RPR tests were performed to identify syphilis. 
Results were compared with similar surveys from past years. Results show a definite trend 
toward declining syphilis rates from 1998 to 2004. A decline from approximately 12% to 2% 
was seen spanning this time period. (See figure 5.)10  
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Figure 5: Syphilis prevalence trends among antenatal clinic attendees: 1997 – 2004 
(Adapted from the National HIV and Syphilis Antenatal Sero-prevalence Survey in South 
Africa 2004) 
 
Such studies show the progress made by our health facilities in the decline of syphilis. 
Despite spanning the nine provinces, such surveys do however have limitations, as testing is 
done in one month only and only incorporates patients who seek antenatal care. They don’t 
include miscarriages due to syphilis and the un-booked patient, who may, for social reasons, 
be at greater risk of the disease. Laboratory statistics may hence prove more valuable as 
access to all such results is possible. 
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CHAPTER 2:  
RPR SEROPREVALENCE RESEARCH 
 
2.1  METHODOLOGY 
 
This study was a retrospective record review conducted at Johannesburg Hospital, Gauteng. 
The patients delivered at Johannesburg Hospital include high risk antenatal clinic patients as 
well as referrals from feeder clinics and secondary level hospitals. All positive RPR tests, 
irrespective of titre were included. The current prevalence was determined by a sample of 
RPR results of patients delivered at Johannesburg Hospital from 1 August 2002 to 31 January 
2003. In addition, period samples were used and the RPR positive prevalence was determined 
for each of these periods. The approximate prevalence for each year from past to current 
periods was determined for two months of each year, six months apart from 1996 to 2002.  In 
order to be representative, February (1 to 28/29) and August (1 to 31) of each of these years 
was chosen. January was avoided as a large number of patients travel in January and do not 
necessarily give birth where they attend antenatal clinic. 
The control group, referred to as ‘past prevalence’ was the patients from the Stewart-Smythe 
study7, which had been conducted on similar lines at the same hospital from 1 January 1995 
to 31 March 1996. Although unpublished, a sample size of 15147 patients was used, these 
patients having given birth at Johannesburg Hospital. 
 
Since data collection was done from labour ward registers, and all patients with available 
results for each specified period were used, bias during data collection was unlikely. 
Laboratory statistics of reactive syphilis serology of pregnant patients who presented to the 
Johannesburg Hospital, including booked and unbooked patients, were analysed in order to 
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confirm trends in RPR seroprevalence. This served to verify the results collected from the 
current period, as laboratory results from prior to the year 2000 could not be obtained. These 
results were not computerized. 
 
Labour ward register reviews were done with the help of collation sheets using the following 
headings: 
• Age 
• Booked/ unbooked 
• Hospital number/ date of delivery 
• RPR ‘positive’/ RPR ‘negative’/ RPR ‘unknown’ 
• HIV ‘positive’/ HIV ‘negative’/ HIV ‘unknown’ 
 
This information was added so that any relevance to the change in RPR positive prevalence 
rate could be determined. Also, congenital syphilis data from 1995-1996 and 2000-2002 was 
collected in order to help identify whether the proposed decrease in RPR positive prevalence 
was indeed a true one (if proven) or if it was likely to be due to a large number of false 
negatives. This information was collected from the records of  the Department of Peadiatrics 
at Johannesburg Hospital. The Centers for Disease Control, for the purposes of notification, 
includes in its definition of congenital syphilis, stillbirths associated with syphilis and the 
infants of mothers who were inadequately treated or untreated for syphilis, irrespective of the 
findings in the infant. This was the definition adhered to in this study.14,15,16 
 
The results of the current study period and each prior year were collated separately to 
determine the trend in RPR positive prevalence. Microsoft Excel software was used to aid 
data entry. Statistical analysis of results of the current period as compared to the 1995 – 1996 
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control group was achieved using EPi-Info 6 statistical software. This analysis was then 
applied to each year between the 2 study periods. The contribution of other factors referred to 
in the collation sheets was also analysed. Comparison of prevalence rates was done using the 
chi-squared test (with statistical significance accepted at p < 0.05) and odds ratios with 95% 
confidence intervals. 
 
Ethics approval was obtained for our study. (Annexure 1) 
 
2.2  RESULTS 
 
The records of 3832 patients were obtained for the current period (August 2002 – January 
2003). Two thousand, nine hundred and five (75.8%) patients were RPR negative; 134 
(3.5%) were RPR positive and 793 (20.7%) did not have RPR results available. 
 
Using known results only, the current prevalence was determined at 4.4%, a statistically 
significant difference being observed when compared to the past prevalence of 19.5% in 
1995/96 (Table 3). Similarly, a statistically significant decrease in rates of congenital syphilis 
was noted (Table 4). 
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Table 3: Comparison of RPR seroprevalence rates in 2002/03 compared with a similar 
sample taken in 1995/96 
 
Sample RPR seropositivity Percent 
2002/2003 134/3039 4.4 
1995/1996 2960/15147 19.5 
Odds ratio = 0.19: 
(95%CI 0.16-0.23) 
(P< 0.0001) 
 
Table 4: Comparison of congenital syphilis prevalence rates in 2002/03 compared with 
those of 1995/96 
 
Sample Congenital syphilis Percent 
2002/2003 102/3089 3.3 
1995/1996 151/1195 12.64 
Odds ratio = 0 24. 
95%CI (0.21-0.33) 
(P< 0.0001)  
 
Verification of results using the laboratory statistics of seropositive pregnant women 
attending Johannesburg hospital for the study period revealed a prevalence rate of 4.8% 
(46/961 patients). This included 34 RPR positive tests and 12 Wasserman Reaction (WR) 
positive tests, which were all charted as RPR positive on the patients’ booking cards. 
Booking results for the whole of 2002 were collected and revealed a seroprevalence rate of 
4.6% (68/1467 patients) of which 66 were RPR positive and 2 were WR positive. From 1 
January 2003 to 22 April 2003 (date when results were collected from the laboratory) the 
seroprevalence was noted to be lower at 3.4% (30/551 patients) of which 11 were RPR 
positive and 19 WR positive. Table 5 illustrates the availability of results for the period 
intervening the past and current study samples.  
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Table 5: Prevalence rates of RPR negative, RPR positive and RPR unknown patients in 
1-month period samples from August 1999 to August 2002 
 
Results Aug 
1999 
Feb 
2000 
Aug 
2000 
Feb 
2001 
Aug 
2001 
Feb 
2002 
Aug 
2002 
No. 173 397 493 433 530 426 476 RPR 
negative % 36.7 68.5 73.5 80.8 82.0 76.9 74.7 
No. 26 29 31 16 26 28 21 RPR 
positive % 5.5 5.0 4.6 3.0 4.0 5.1 3.3 
No. 272 157 147 87 90 100 140 RPR 
unknown % 57.8 26.6 21.9 16.2 13.9 18.1 21.9 
Total results 471 583 671 536 646 554 637 
Total known 
results 
199 426 524 449 556 454 497 
Known RPR 
prevalence 
13.1% 6.8% 5.9% 3.6% 4.7% 6.2% 4.2% 
Aug=August, Feb=February. 
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2.3 DISCUSSION 
 
The observed decrease in the prevalence of positive RPR tests was statistically significant, 
the past period (1995 -1996) having had a RPR seropositivity rate of 19.5% as opposed to the 
current period (2002 – 2003) having a rate of 4.4%.  
 
Figure 6:  RPR seroprevalence rate progression from 1995/96 to 2002/03 
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The prevalence each year, from past to current periods, initially showed a statistically 
significant decrease followed by a stabilization in the prevalence, showing that the decrease is 
not linear but rather hyperbolic (Figure 6). This is extremely important as the RPR test is 
used as a marker for syphilis and, being an infectious disease, one needs to exclude the 
possibility of the decrease frequently observed during a ‘seasonal’ low. The fact that the 
decline in prevalence has been consistent and now stabilized makes this phenomenon 
unlikely with syphilis since the study in its comparison has spanned a period of seven years. 
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Also, since this study has dealt with the RPR seroprevalence rate, irrespective of titre, the true 
syphilis rate is likely to be even lower, as it is known that a large number of low-titre RPR 
positive results are false positives.2,3,42 
 
With the decrease in the prevalence of RPR seropositivity it was important to assess whether 
there was a concomitant decrease in the rate of congenital syphilis. This was also noted with 
the prevalence decreasing from 12.6% in the past period (1995-1996) to a prevalence rate of 
3.3% in the current period (2002 – 2003).  
 
Although these results were obtained from the Johannesburg Hospital, statistics from another 
large local centre, Chris Hani Baragwanath Hospital, revealed 70 deaths from congenital 
syphilis in 1995, 11 in the year 2000, 8 in 2001 and just 6 in 2002, thus also showing a 
progressive decline in prevalence. 
 
The concurrent and progressive decrease in the prevalence of congenital syphilis suggests 
that there has indeed been a true decrease in RPR seroprevalence from 1995 to 2003. The 
rates appear to have stabilized at between 4 and 6 %. If this is true nationwide, retesting in the 
third trimester, as previously suggested in areas of high prevalence44, may no longer be an 
issue. Potential causes of the observed decrease in this study are many, including: 
• Changes in the test characteristics with possible impaired sensitivity 
• Changes in patient profile 
• Potentially incorrect statistics in 1995 
• A type 1 statistical error 
• HIV effects on test characteristics 
• Widespread antibiotic use 
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• Termination of pregnancy 
• Miscarriages 
• Sampling technique 
 
The laboratory servicing the Johannesburg Hospital denies any changes in the test 
characteristics since 1995. Patients may well differ with education, improved psychosocial 
support structures, socio-economic upliftment, better nutrition and a greater awareness of safe 
sexual practices; although there is no obvious evidence that sexual practices have changed or 
usage of condoms has increased to such a degree to substantiate the decline in prevalence of 
syphilis. A type 1 error is improbable as the p values are extremely low. In HIV infected 
individuals, serological tests such as the RPR tests, which are based on the immune response 
of the individual, may well be falsely negative in both early and late stages of the disease due 
to deregulation of the immune responses.36,37 
 
Widespread antibiotic use, especially with the high prevalence of HIV in the general 
population, and with the advent of syndromic management for sexually transmitted 
infections, may well account for the decrease in the prevalence of syphilis and hence RPR 
positive tests in the general population as well as the pregnant population.2,19 In the 
penicillin-allergic, non-pregnant patient, syphilis can be treated with doxycycline, 
tetracycline, ceftriaxone and azithromycin.2 These are all commonly used antibiotics so 
patients may well be treated unwittingly before they fall pregnant. 
 
Termination of pregnancy and miscarriages may also mask the prevalence of positive RPR 
tests as many of these patients are not tested for syphilis and syphilis may itself be a causative 
factor in miscarriages after the first trimester and these patients would not reach the labour 
ward and be included in the RPR positive statistics. Frequent unprotected sexual intercourse 
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is a recognized risk factor for both STIs, unwanted pregnancies and termination of 
pregnancy. 
 
Sampling technique problems are unlikely to have caused bias in this study. A number of 
verification exercises were undertaken as described above. 
 
Limitations 
The discussion has highlighted a number of limitations inherent in a study of this nature. The 
potential causes of a decrease in the prevalence of RPR positive tests as mentioned above 
could not be fully investigated.  
 
Sampling of all patients delivered in the Johannesburg Hospital labour ward necessitated 
inclusion of patients referred to this tertiary labour ward from other institutions. All referral 
letters however did not come with the RPR and/or HIV results of these patients. 
 
A number of verification procedures were done to obviate the above limitations where 
possible. The results of these procedures correlated well with the results of the study. The 
study however could not be based purely on laboratory results, as results from the laboratory 
were only available after the year 2000 on computer and previous results could not be 
obtained as laboratory registers are only kept for three months now that all results are charted 
on computer. The advantage of laboratory results though is that they include the results of 
blood tests of unbooked patients that were not in labour ward registers at the time of delivery 
but had been sent to the laboratory on admission. 
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Implications 
Current practice dictated by our national guidelines includes routine testing for syphilis in the 
pregnant population with non-specific tests and treatment of all positive results irrespective of 
titre. This has implications to both the patient and the health system. Treatment of a possible 
false positive test result may negatively affect the patient’s morale and relationship with her 
partner, as syphilis is a sexually transmitted disease and benzathine penicillin injections are 
extremely painful. However, specific serological tests for syphilis are expensive, results take 
longer and the longer a patient is left untreated, the greater the chance of repeated exposure, 
mid-trimester miscarriages, stillbirths and congenital syphilis. 
 
For this reason as well as the fact that the decrease in congenital syphilis is indeed a positive 
outcome measure, I recommend that current practice still be continued until further studies 
are conducted in the different regions of South Africa. A similar study from Addington 
Hospital, KwaZulu Natal showed similar results.54 
 
In the long term, it is reassuring to know that the RPR positive rate and hence the syphilis 
rate is approaching that of first world countries.1 Natural syphilis is a disease exclusive to 
humans1, not unlike poliomyelitis, and hence has the potential of being eradicated. It is 
possible that the current national guidelines of treatment irrespective of titre may have 
contributed to the decreasing prevalence rates of the condition in South Africa. Contact 
tracing is essential if male partners involved in spread of the disease are to be identified and 
treated. Perhaps testing for syphilis with RPR tests should be done at all consultations for 
sexually transmitted disease as well as all termination of pregnancy sites.12,19 If this is done as 
an active attempt to eradicate the disease, prevalence rates could drop further. Routine 
treatment of a positive result irrespective of titre could become unnecessary as fewer specific 
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tests would be needed and patients would no longer need to be treated for false positive 
results. 
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CONCLUSION 
 
RPR positive prevalence rates at the Johannesburg hospital have decreased significantly since 
1995. The concurrent drop in the prevalence rate of congenital syphilis suggests that this is a 
true rather than an assumed decrease. The prevalence seems to have stabilized over the last 
few years. The implications of this lower RPR positive prevalence rate and the causes thereof 
are numerous and warrant further investigation. 
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